RT Conference Proceedings
T1 Prognostic value of a high level of circulating endothelial cells in  patients with HER2-recurrent or metastatic breast cancer treated  with bevacizumab in combination with paclitaxel and gemcitabine  as fi  rst-line therapy
A1 Manso, L
A1 Ciruelos, E
A1 Codes, M
A1 De la Haba, J
A1 Galan, A
A1 Baena, J
A1 Jaen, A
A1 Gil, M
A1 Murias, A
A1 Blancas, I
A1 Gonzalez, E
A1 Perez, D
A1 Bayo, JL
A1 Mel, J
A1 Garcia-Martinez, E
A1 Cubedo, R
A1 Salvador, J
K1 Neoplasias
K1 Bevacizumab
K1 Anticuerpos monoclonales humanizados
K1 Desoxicitidina
K1 Progresión de la enfermedad
K1 Células endoteliales
K1 Paclitaxel
AB Circulating endothelial cells (CECs) are shed from vessels and enter the circulation reflecting endothelial damage. Increased numbers of CECs have been documented in cancer, and appear to correlate with progression of the tumor. Bevacizumab (B) in combination with CT improves progression-free survival (PFS) of first-line treatments and may modify tumor cell intravasation and CEC/CTC levels.
PB BioMed Central
SN 1465-5411
YR 2011
FD 2011-11-16
LK http://hdl.handle.net/10668/2231
UL http://hdl.handle.net/10668/2231
LA en
NO Manso L, Ciruelos E, Codes M, De la Haba J, Galan A, Baena J, et al. Prognostic value of a high level of circulating endothelial cells in  patients with HER2-recurrent or metastatic breast cancer treated  with bevacizumab in combination with paclitaxel and gemcitabine  as fi  rst-line therapy. Breast Cancer Res. 2011; 13(Suppl 2): P4.
DS RISalud
RD Apr 10, 2025